As part of our ongoing aim to bring you reports of significant developments, we have added a review of safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis.
Independent commentary is provided by Associate Professor Patricia Lowe, a senior staff specialist in Dermatology at Royal Prince Alfred Hospital and Clinical Associate Professor at the University of Sydney.
Please login below to download this issue (PDF)